SI/II Pocket of Ras: An Opportunity for a Once "Undruggable" Target

Tanos C C França1,2,3, Michael Maddalena4,5, Imène Kouidmi4,5

  • 1INRS Centre Armand Frappier Santé Biotechnologie, 531 des Prairies Boulevard, Laval, Quebec H7 V 1B7, Canada.

ACS Omega
|March 17, 2025
PubMed

Insights

Ras mutations drive cancer, but the SI/II pocket offers a new therapeutic target. This pocket is accessible in the GTP-bound state, suggesting it’s a promising site for novel Ras inhibitors.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Ras GTPases are key oncogenic drivers, particularly HRas in head-and-neck and genitourinary cancers.
  • The previously undruggable Ras family now presents a potential target: the conserved SI/II pocket near the SOS1 binding site.

Purpose of the Study:

  • To characterize the SI/II pocket's topology in GDP-bound HRasG12V.
  • To investigate the conformational dynamics of the SI/II pocket in different HRas states.

Main Methods:

  • Generated a crystal structure of native GDP-bound HRasG12V.
  • Utilized molecular dynamics simulations on native and synthetic HRas models.
  • Analyzed structures of GDP-bound and GppNHp-bound HRasG12V.

Main Results:

  • The SI/II pocket is inaccessible in native GDP-bound HRas.
  • The pocket becomes accessible in the GppNHp-bound state, especially in mutated HRas.
  • The α2 helix and residue Y71 control pocket accessibility via a 'tyrosine toggle' mechanism.

Conclusions:

  • The GTP-bound state of HRas is the most promising target for SI/II pocket-directed Ras inhibitors.
  • Understanding the SI/II pocket's dynamics is crucial for developing pan-Ras drugs.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K